Breast Surgery
M-A | Margin status and survival outcomes after breast cancer conservation surgery.
23 Sep, 2022 | 13:09h | UTCCommentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ
News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom
RCT | Multiple doses of prophylactic intravenous antibiotics are no better than a single dose in implant-based breast reconstruction.
19 Sep, 2022 | 12:48h | UTC
Commentary on Twitter
Multiple-dose antibiotic prophylaxis was not superior to a single-dose regimen in preventing surgical site infection and implant removal after implant-based breast reconstruction in this RCT. https://t.co/p7GbNRMPfW #OAResarch
— JAMA Network Open (@JAMANetworkOpen) September 16, 2022
Cohort Study | Fertility preservation procedures appear to be safe at the time of breast cancer diagnosis.
7 Sep, 2022 | 12:31h | UTCNews Release: Fertility preservation measures do not appear to increase the risk of breast cancer recurrence – Karolinska Institutet
Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.
31 Aug, 2022 | 11:45h | UTCDe-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
At 5-year follow up in RAPCHEM, BOOG 2010–03 study of locoregional RT de-escalation in cT1-2N1 breast cancer, locoregional recurrence rates were 2.3%, 1.0% and 1.4% in low, intermediate and high risk groups, and therefore this approach was considered safe: https://t.co/4NkUwr4kxV
— NatureRevClinOncol (@NatRevClinOncol) August 15, 2022
Spindle cell lesions of the breast: a diagnostic algorithm.
23 Aug, 2022 | 12:51h | UTC
RCT | Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast.
9 Aug, 2022 | 12:46h | UTCRadiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
Cohort Study | Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
9 Aug, 2022 | 12:20h | UTC
Commentary on Twitter
Out on NPJ Breast a new report on #ERlowtumors. No difference in characteristics, pCR rates, RFS os OS compared with #TNBC. Patients with ER-low tumors should be treated as for TNBC. Also, important confounder to remember in HER2-low prognostic analyses.https://t.co/M1GF8eyYbT pic.twitter.com/CrLyUgyhUV
— Paolo Tarantino (@PTarantinoMD) July 11, 2022
RCT | Partial breast irradiation vs. whole breast irradiation for early breast cancer.
8 Aug, 2022 | 11:36h | UTCPartial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
M-A | Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction.
28 Jul, 2022 | 13:05h | UTC
NCCN Updated Guideline: Breast cancer.
20 Jun, 2022 | 01:24h | UTC
Cohort Study: Association of screening with digital breast tomosynthesis vs. digital mammography with risk of interval invasive and advanced breast cancer.
17 Jun, 2022 | 11:09h | UTCAssociation of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer – JAMA (free for a limited period)
Editorial: Digital Breast Tomosynthesis and Detection of Interval Invasive and Advanced Breast Cancers – JAMA (free for a limited period)
News Release: 3-D Mammography Technique Benefits Some Women, Not All – University of California San Francisco
Regional lymphadenopathy following COVID-19 vaccination in patients with or suspicious of breast cancer: a quick summary of current key facts and recommendations.
14 Jun, 2022 | 11:07h | UTCRelated:
2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients
Circulating tumor DNA and late recurrence in high-risk hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer.
13 Jun, 2022 | 07:35h | UTCCommentary: Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in Advance — First evidence for patients in late adjuvant setting, years after initial diagnosis – MedPage Today (free registration required)
Commentary on Twitter
103 women in long-term remission from high-risk HR+/HER2- breast cancer had customized monitoring of recurrence based on ctDNA seq for tumour-associated mut. Among 8 pts MRD+ pts, 6 developed distant recurrence at a median 12.4 mo after ctDNA positivity https://t.co/aX1ruLCSbb
— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022
Cohort Study: Long-term quality of life in patients with breast cancer after breast conservation vs mastectomy and reconstruction.
9 Jun, 2022 | 10:30h | UTCLong-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction – JAMA Surgery (link to abstract – $ for full-text)
Commentaries:
Long-Term QOL Examined for Surgical Choices in Breast Cancer – HealthDay
Commentary on Twitter
Survey of #breastcancer survivors after treatment found:
1. Breast satisfaction and physical well-being similar with lumpectomy+rads or mastectomy+reconstruction (no rads)
2. Psychosocial well-being and sexual well-being better with lumpectomy+rads https://t.co/tPh9Pt4gYx— JAMA Surgery (@JAMASurgery) April 14, 2022
Phase 2 RCT: Efficacy of epigallocatechin-3-gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy.
2 Jun, 2022 | 10:34h | UTCEfficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Visual Abstract: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy
RCT: Effect of supine vs. prone breast radiotherapy on acute toxic effects of the skin among women with large breast size.
27 May, 2022 | 11:51h | UTCEffect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: Prone Whole-Breast Radiotherapy—Better Than Supine? (free for a limited period)
Commentary on Twitter
Adjuvant breast radiotherapy in the prone position decreases acute skin toxicity in women with large breast size, as demonstrated by this multicenter randomized clinical trial. https://t.co/6Emr2Hy5KH #BCSM #RadOnc
— JAMA Oncology (@JAMAOnc) May 26, 2022
Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.
26 May, 2022 | 10:42h | UTC
RCT: The addition of Metformin to standard therapy did not improve outcomes in patients with breast cancer.
25 May, 2022 | 11:49h | UTCEffect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Who Will Benefit From Metformin? – JAMA Oncology
Top 100 most-cited articles on enhanced recovery after surgery.
24 May, 2022 | 10:38h | UTCSee also: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Mammographic breast density, benign breast disease, and subsequent breast cancer risk in 3.9 million Korean women.
19 May, 2022 | 10:51h | UTCNews Release: Density, benign disease raise risk of breast cancer – Radiological Society of North America
Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy – A prospective interventional study.
19 May, 2022 | 10:15h | UTC
Nonrandomized Controlled Trial: Clinical impact of intraoperative margin assessment in breast-conserving surgery with a novel Pegulicianine Fluorescence–guided system.
18 May, 2022 | 10:28h | UTC
Commentary on Twitter
New intraoperative margin detection technology is safe and reduces reexcision rates in patients undergoing breast conserving surgery! (include infographic) #bcsm https://t.co/NqUOhGJBo4
— JAMA Surgery (@JAMASurgery) May 11, 2022
Retrospective Cohort Study: Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer.
9 May, 2022 | 01:40h | UTC
Commentary on Twitter
BD-IPMN 🍇 at very low risk of cancer 🔎 how to identify patients for surveillance
🌐 Multicentre Pancreas 2000 study of @EurPancClub
⚠️ 20% develop WF/HRS at FU
🏁 80% with WF/HRS still surveilled safely👉 MOST BD IPMN will never need surgery 👈https://t.co/YPHaQd98u1 pic.twitter.com/ypglRlNR2q
— Giovanni Marchegiani (@Gio_Marchegiani) May 7, 2022
Recommendations for breast cancer screening in women with extremely dense breasts.
4 May, 2022 | 08:11h | UTC
RCT: Digital breast tomosynthesis plus synthesized mammography versus digital screening mammography for the detection of invasive breast cancer.
1 May, 2022 | 23:14h | UTCDigital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial – The Lancet Oncology (link to abstract – $ for full-text)